Smell reveal sits at the center of this dementia and brain health question.

Yes, your sense of smell could indeed reveal your Alzheimer’s risk—and it may do so earlier than memory loss or cognitive decline appears. Research increasingly shows that olfactory dysfunction is one of the earliest detectable signs of Alzheimer’s disease, emerging before the symptoms most people associate with cognitive decline. For example, someone who suddenly notices they can’t smell their morning coffee as strongly as before, or can’t detect familiar odors they once savored, may already be experiencing neurological changes linked to Alzheimer’s risk.

Recent studies have found that immune cells attack brainstem nerve fibers connected to smell, making olfactory loss a potential early warning system for brain changes ahead. This article explores what research reveals about the connection between smell and Alzheimer’s risk, how scientists are now testing this link through simple at-home assessments, and what these findings mean for early detection and intervention. Understanding this relationship could reshape how we approach brain health in aging, since new treatments for Alzheimer’s work best when applied early—before significant brain damage occurs.

Why Does Smell Loss Signal Alzheimer’s Risk?
The Statistical Evidence Linking Smell Decline to Cognitive Risk
How Smell Tests Can Predict Cognitive Decline
The New At-Home Smell Test for Brain Health
Understanding the Limitations and False Positives
Why Early Detection Matters Now More Than Ever
The Future of Smell-Based Brain Health Screening
Conclusion

Why Does Smell Loss Signal Alzheimer’s Risk?

The connection between olfactory function and Alzheimer’s disease isn’t coincidental. Smell is one of the most direct routes to the brain, with olfactory neurons extending from the nasal cavity directly into the olfactory bulb, a region deeply involved in memory formation. When Alzheimer’s pathology begins to develop—including the buildup of amyloid-beta and tau proteins—the olfactory system is often among the first areas affected.

research has shown that immune cells may actually attack brainstem nerve fibers linked to smell, disrupting the neural signals that let us detect and identify odors. This early vulnerability means that a declining sense of smell can serve as a biological marker of what’s happening inside the brain long before memory problems become noticeable. Studies have found that olfactory loss emerges as one of the earliest behavioral signs of Alzheimer’s disease, sometimes appearing years before cognitive symptoms. For comparison, many people notice memory slips only after significant neurological damage has already accumulated—but smell may flag risk much sooner, potentially creating a window for early intervention.

Why Does Smell Loss Signal Alzheimer's Risk?

The Statistical Evidence Linking Smell Decline to Cognitive Risk

The numbers tell a compelling story. A 2025 meta-analysis found that decline in olfactory function increases the risk of cognitive impairment in normal individuals by 83%—a substantial and consistent increase across multiple studies. this isn’t a marginal effect; the confidence interval (95% CI [1.41–2.38]) means researchers are quite certain of this association. For those already experiencing mild cognitive impairment, the stakes are higher. Olfactory decline increases the risk of progression from MCI to Alzheimer’s disease (OR = 1.52, 95% CI [1.16–1.99]).

Even more striking, rapid olfactory decline during normal cognition predicted an 89% higher incidence of subsequent mild cognitive impairment or dementia—a risk comparable to carrying an APOE-ε4 allele, one of the most powerful genetic risk factors for Alzheimer’s. This matters because genetic risk is typically something we can’t change, while smell testing is something anyone can do. As for prevalence, olfactory dysfunction is common but increases sharply with age. About 13% of people in their 60s experience olfactory dysfunction, but that rises to 48% of people in their 80s. This age-related increase creates both a challenge and an opportunity: more people at risk of dementia need screening, and simple smell tests could potentially identify them before symptoms progress.

How Smell Tests Can Predict Cognitive Decline

The diagnostic power of smell testing has become remarkably specific. In patients with mild cognitive impairment, odor identification test scores at or below 34 predicted conversion to Alzheimer’s dementia within 5 years with 90% sensitivity and 50% specificity. Sensitivity this high means that if a person has low smell scores, there’s a strong likelihood they’re moving toward Alzheimer’s. Specificity at 50% means the test produces false positives—not everyone with low scores will develop Alzheimer’s—but that’s often acceptable in screening, since a positive result prompts closer monitoring rather than immediate diagnosis.

What makes this compelling for early detection is timing. Current diagnostic approaches often rely on cognitive testing (which may not detect changes until brain damage is advanced) or expensive imaging like PET scans that look for amyloid or tau. Smell testing could identify at-risk individuals years before these other markers become evident, potentially during a critical window when new treatments might prevent or slow cognitive decline. However, smell testing alone isn’t sufficient for diagnosis—it’s best used as part of a broader evaluation that includes memory and thinking assessments.

How Smell Tests Can Predict Cognitive Decline

The New At-Home Smell Test for Brain Health

In 2025, researchers at Mass General Brigham developed the AROMHA Brain Health Test, an at-home assessment designed to detect early cognitive decline through olfaction. The test includes three components: odor perception identification (can you identify what something smells like?), odor episodic memory (can you remember a smell you experienced earlier?), and odor discrimination testing (can you tell the difference between similar smells?). In clinical studies, older adults with mild cognitive impairment scored significantly lower than cognitively normal adults across all three components.

One of the most practical findings is that simple smell tests combined with memory tests proved as effective at predicting cognitive decline as expensive amyloid imaging—a neuroimaging method that costs thousands of dollars and requires specialized equipment. The at-home test was equally successful across English and Spanish speakers and worked whether researchers supervised the testing or not. This accessibility is crucial because it could democratize early detection, allowing people to assess their risk in their own homes rather than waiting for access to specialized neuroimaging clinics. However, at-home testing requires honesty and careful attention to instructions—rushing through the test or not following directions precisely could affect results.

Understanding the Limitations and False Positives

While smell testing is promising, it’s important to understand what it can and cannot tell you. A decline in smell doesn’t automatically mean Alzheimer’s is developing. Olfactory loss has many causes, including chronic nasal congestion, sinus infections, COVID-19, smoking, and normal aging. Someone with a stuffy nose might score poorly on a smell test without any Alzheimer’s-related pathology.

This is why researchers found 50% specificity—meaning the test generates false alarms in people who will not develop Alzheimer’s. Additionally, smell testing works best as part of a comprehensive evaluation. If you notice declining smell combined with memory problems, trouble finding words, or difficulty following conversations, that pattern is more concerning than smell loss alone. Conversely, normal smell function doesn’t rule out Alzheimer’s risk entirely; it simply suggests the olfactory system hasn’t been affected yet. The value of smell testing lies in its ability to identify a subset of people at particularly high risk who might benefit from closer monitoring, cognitive testing, or lifestyle interventions known to support brain health.

Understanding the Limitations and False Positives

Why Early Detection Matters Now More Than Ever

For decades, Alzheimer’s treatment has been frustratingly limited because most people received diagnosis or treatment only after substantial brain damage had occurred. But recent approval of amyloid-targeting antibody therapies like lecanemab has changed the calculus. These drugs can slow cognitive decline in people with amyloid accumulation, but they work best when given early—ideally when someone has mild cognitive impairment or even earlier, before major symptoms appear.

Smell testing could help identify candidates for these early interventions years before they’d normally be diagnosed. Someone who notices declining smell and shows other early markers might benefit from amyloid imaging and, if appropriate, from newer therapies that could prevent the progression to full dementia. This represents a fundamental shift from treating Alzheimer’s once it’s symptomatic to identifying and intervening in people with preclinical pathology.

The Future of Smell-Based Brain Health Screening

As research continues, smell testing may become a routine part of brain health assessment, similar to how blood pressure monitoring is standard in general health care. The ease and low cost of smell testing—compared to imaging or spinal fluid analysis—makes it an attractive screening tool for primary care physicians, neurologists, and even geriatric specialists.

Future developments might include more sophisticated at-home tests, better integration with memory testing, and research into whether interventions targeting olfactory function itself could help preserve cognitive health. The field is also exploring whether smell loss might predict other neurodegenerative conditions beyond Alzheimer’s, including Parkinson’s disease and Lewy body dementia. As our understanding of how Alzheimer’s begins to develop deepens, smell—once overlooked as a neurological marker—may become a key part of the strategy for catching the disease early enough to make a real difference.

Conclusion

Your sense of smell tells a story about your brain that goes far beyond whether you can enjoy the aroma of dinner. Olfactory decline is now recognized as one of the earliest behavioral signs of Alzheimer’s disease, increasing cognitive impairment risk by 83% and progression risk from mild cognitive impairment to dementia by 52%. The emergence of affordable, at-home smell tests like the AROMHA Brain Health Test makes it practical for anyone concerned about cognitive health to assess this important marker.

If you’re noticing a decline in your sense of smell—especially if it’s rapid or accompanied by other cognitive changes—discussing smell testing with your doctor is worth considering. While smell loss alone doesn’t mean Alzheimer’s is inevitable, it’s a signal worth investigating as part of a broader assessment of brain health. With new treatments now available that work best when applied early, the ability to detect Alzheimer’s risk years before memory loss appears could transform outcomes for millions of people.